Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Cullinan Oncology contributed to a series A round that funded the launch of a cancer drug-focused joint venture with PDI Therapeutics.

GV, a corporate venturing subsidiary of internet and technology group Alphabet, has led a $63m series A2 round for Verve Therapeutics, a US-based developer of genomic heart disease drugs.

University of Cambridge stem cell differentiation spinout Bit Bio secured $41.5m from investors including Arch Venture Partners to boost its overall funding to $50m.

Muscle disease drug developer Avidity, which counts Eli Lilly, EMS, Takeda and ST Pharm as investors, went public in a significantly upized IPO.

Tencent-backed telemedicine service Miaoshou Doctor pulled in $84.5m that will support the strengthening of its health insurance provision.

Genomic heart disease drug developer Verve Therapeutics secured funding in a round led by GV, which also led its series A last year.

GenScript Biotech's spinoff Legend Biotech, which counts Eli Lilly and Johnson & Johnson as backers, floated in the US.

The emergency response software provider, which counts AAA, CSAA, Microsoft and Motorola Solutions as investors, lifted its total funding to $107m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.